Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Research & Development: 2020-2024

Historic Research & Development for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $143.9 million.

  • Tango Therapeutics' Research & Development fell 7.36% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.0 million, marking a year-over-year decrease of 5.18%. This contributed to the annual value of $143.9 million for FY2024, which is 24.93% up from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Research & Development is $143.9 million, which was up 24.93% from $115.2 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' Research & Development peaked at $143.9 million during FY2024, and registered a low of $50.0 million during FY2020.
  • For the 3-year period, Tango Therapeutics' Research & Development averaged around $121.7 million, with its median value being $115.2 million (2023).
  • Data for Tango Therapeutics' Research & Development shows a peak YoY spiked of 55.30% (in 2021) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Research & Development (Yearly) stood at $50.0 million in 2020, then surged by 55.30% to $77.6 million in 2021, then spiked by 36.41% to $105.9 million in 2022, then rose by 8.77% to $115.2 million in 2023, then increased by 24.93% to $143.9 million in 2024.